Northern Trust: Lineage Cell Therapeutics LCTX Historial de posiciones en acciones
Comprado
Mantenidas
Vendido
| Trimestre | Valor de mercado | Estado | Acciones |
Cambio en la posición | Valor operado | Peso en el portafolio | Puesto en el portafolio | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | USD 1.58 M | Compra |
1,657,655
+1,004
| +0.1% | +USD 1.11 k | ﹤0.01% | 3196 |
|
|
2026
Q2 | USD 2.17 M | Compra |
1,656,651
+1,157,524
| +232% | +USD 1.6 M | ﹤0.01% | 3089 |
|
|
2026
Q1 | USD 789 k | Compra |
499,127
+19,854
| +4% | +USD 33.5 k | ﹤0.01% | 3442 |
|
|
2025
Q4 | USD 800 k | Compra |
479,273
+35,921
| +8% | +USD 62.2 k | ﹤0.01% | 3473 |
|
|
2025
Q3 | USD 749 k | Venta |
443,352
-67,110
| -13% | -USD 79.4 k | ﹤0.01% | 3519 |
|
|
2025
Q2 | USD 463 k | Venta |
510,462
-1,029,124
| -67% | -USD 610 k | ﹤0.01% | 3671 |
|
|
2025
Q1 | USD 695 k | Compra |
1,539,586
+265,094
| +21% | +USD 155 k | ﹤0.01% | 3433 |
|
|
2024
Q4 | USD 640 k | Venta |
1,274,492
-81
| -0% | -USD 59 | ﹤0.01% | 3567 |
|
|
2024
Q3 | USD 1.15 M | Compra |
1,274,573
+83,255
| +7% | +USD 77.2 k | ﹤0.01% | 3302 |
|
|
2024
Q2 | USD 1.19 M | Venta |
1,191,318
-41,228
| -3% | -USD 45.5 k | ﹤0.01% | 3169 |
|
|
2024
Q1 | USD 1.82 M | Compra |
1,232,546
+37,362
| +3% | +USD 42.4 k | ﹤0.01% | 3007 |
|
|
2023
Q4 | USD 1.3 M | Venta |
1,195,184
-8,773
| -0.7% | -USD 9.6 k | ﹤0.01% | 3216 |
|
|
2023
Q3 | USD 1.42 M | Compra |
1,203,957
+100,825
| +9% | +USD 137 k | ﹤0.01% | 3120 |
|
|
2023
Q2 | USD 1.56 M | Compra |
1,103,132
+866,049
| +365% | +USD 1.2 M | ﹤0.01% | 3160 |
|
|
2023
Q1 | USD 356 k | Compra |
237,083
+13,633
| +6% | +USD 19 k | ﹤0.01% | 3595 |
|
|
2022
Q4 | USD 261 k | Sin cambios |
223,450
| – | – | ﹤0.01% | 3739 |
|
|
2022
Q3 | USD 252 k | Compra |
223,450
+21,675
| +11% | +USD 31.8 k | ﹤0.01% | 3759 |
|
|
2022
Q2 | USD 319 k | Venta |
201,775
-829,034
| -80% | -USD 1.09 M | ﹤0.01% | 3701 |
|
|
2022
Q1 | USD 1.59 M | Venta |
1,030,809
-50,115
| -5% | -USD 77.8 k | ﹤0.01% | 3207 |
|
|
2021
Q4 | USD 2.65 M | Venta |
1,080,924
-416,703
| -28% | -USD 975 k | ﹤0.01% | 3080 |
|
|
2021
Q3 | USD 3.77 M | Venta |
1,497,627
-131,122
| -8% | -USD 336 k | ﹤0.01% | 2920 |
|
|
2021
Q2 | USD 4.64 M | Compra |
1,628,749
+1,332,456
| +450% | +USD 3.45 M | ﹤0.01% | 2880 |
|
|
2021
Q1 | USD 696 k | Compra |
296,293
+34,264
| +13% | +USD 82.3 k | ﹤0.01% | 3719 |
|
|
2020
Q4 | USD 461 k | Venta |
262,029
-7,027
| -3% | -USD 9.8 k | ﹤0.01% | 3747 |
|
|
2020
Q3 | USD 252 k | Compra |
269,056
+25,921
| +11% | +USD 22.9 k | ﹤0.01% | 3764 |
|
|
2020
Q2 | USD 211 k | Venta |
243,135
-1,039,421
| -81% | -USD 915 k | ﹤0.01% | 3747 |
|
|
2020
Q1 | USD 1.06 M | Compra |
1,282,556
+124,855
| +11% | +USD 124 k | ﹤0.01% | 3192 |
|
|
2019
Q4 | USD 1.03 M | Venta |
1,157,701
-43,658
| -4% | -USD 36.4 k | ﹤0.01% | 3386 |
|
|
2019
Q3 | USD 1.18 M | Venta |
1,201,359
-42,023
| -3% | -USD 43.5 k | ﹤0.01% | 3337 |
|
|
2019
Q2 | USD 1.37 M | Compra |
1,243,382
+11,067
| +0.9% | +USD 12.8 k | ﹤0.01% | 3250 |
|
|
2019
Q1 | USD 1.61 M | Compra |
1,232,315
+238,762
| +24% | +USD 297 k | ﹤0.01% | 3195 |
|
|
2018
Q4 | USD 907 k | Venta |
993,553
-146,524
| -13% | -USD 224 k | ﹤0.01% | 3395 |
|
|
2018
Q3 | USD 2.34 M | Venta |
1,140,077
-21,469
| -2% | -USD 45.1 k | ﹤0.01% | 3129 |
|
|
2018
Q2 | USD 2.09 M | Compra |
1,161,546
+56,896
| +5% | +USD 115 k | ﹤0.01% | 3184 |
|
|
2018
Q1 | USD 2.6 M | Compra |
1,104,650
+54,815
| +5% | +USD 129 k | ﹤0.01% | 2970 |
|
|
2017
Q4 | USD 1.98 M | Compra |
1,049,835
+58,153
| +6% | +USD 127 k | ﹤0.01% | 3145 |
|
|
2017
Q3 | USD 2.46 M | Compra |
991,682
+619,041
| +166% | +USD 1.53 M | ﹤0.01% | 3054 |
|
|
2017
Q2 | USD 1.03 M | Venta |
372,641
-643,337
| -63% | -USD 1.8 M | ﹤0.01% | 3438 |
|
|
2017
Q1 | USD 3.07 M | Compra |
1,015,978
+167,504
| +20% | +USD 476 k | ﹤0.01% | 2853 |
|
|
2016
Q4 | USD 2.68 M | Compra |
848,474
+33,168
| +4% | +USD 102 k | ﹤0.01% | 2928 |
|
|
2016
Q3 | USD 2.78 M | Compra |
815,306
+15,062
| +2% | +USD 41.6 k | ﹤0.01% | 2886 |
|
|
2016
Q2 | USD 1.83 M | Compra |
800,244
+84,567
| +12% | +USD 207 k | ﹤0.01% | 3089 |
|
|
2016
Q1 | USD 1.8 M | Venta |
715,677
-25,716
| -3% | -USD 57.4 k | ﹤0.01% | 3047 |
|
|
2015
Q4 | USD 2.45 M | Compra |
741,393
+59,046
| +9% | +USD 176 k | ﹤0.01% | 2931 |
|
|
2015
Q3 | USD 1.65 M | Compra |
682,347
+32,400
| +5% | +USD 83.9 k | ﹤0.01% | 3141 |
|
|
2015
Q2 | USD 1.9 M | Venta |
649,947
-3,479
| -0.5% | -USD 13.5 k | ﹤0.01% | 3088 |
|
|
2015
Q1 | USD 2.62 M | Compra |
653,426
+631
| +0.1% | +USD 2.18 k | ﹤0.01% | 2952 |
|
|
2014
Q4 | USD 1.96 M | Venta |
652,795
-17,043
| -3% | -USD 46.1 k | ﹤0.01% | 3114 |
|
|
2014
Q3 | USD 1.7 M | Compra |
669,838
+123,598
| +23% | +USD 298 k | ﹤0.01% | 3204 |
|
|
2014
Q2 | USD 1.34 M | Venta |
546,240
-24,051
| -4% | -USD 54.3 k | ﹤0.01% | 3282 |
|
|
2014
Q1 | USD 1.52 M | Venta |
570,291
-44,053
| -7% | -USD 130 k | ﹤0.01% | 3259 |
|
|
2013
Q4 | USD 1.78 M | Compra |
614,344
+9,847
| +2% | +USD 29.8 k | ﹤0.01% | 3208 |
|
|
2013
Q3 | USD 1.85 M | Compra |
604,497
+53,812
| +10% | +USD 170 k | ﹤0.01% | 3131 |
|
|
2013
Q2 | USD 1.76 M | Compra |
+550,685
| Nuevas | +USD 1.76 M | ﹤0.01% | 3061 |
|
Otros fondos que tienen LCTX en su portafolio
Posición de Northern Trust en LCTX: resumen de T3 2026
Northern Trust aumentó su participación en Lineage Cell Therapeutics (LCTX) en 0.06% durante T3 2026, al comprar aproximadamente USD 1.11 k y elevar la posición a 1,657,655 acciones con un valor de USD 1.58 M. La posición representa ﹤0.01% del portafolio y ocupa el puesto #3196.
Northern Trust reportó por primera vez una posición en LCTX en T2 2013 y desde entonces la ha mantenido en 54 trimestres. La posición alcanzó su máximo de USD 4.64 M en T2 2021. Al cierre de T3 2026, 143 fondos que sigue Wall St. Rank mantienen una posición en LCTX.
- Al cierre de T3 2026, Northern Trust tenía 1,657,655 acciones de Lineage Cell Therapeutics con un valor de USD 1.58 M.
- Northern Trust compró 1,004 acciones de Lineage Cell Therapeutics en T3 2026, por un monto estimado de USD 1.11 k.
- Lineage Cell Therapeutics representó el ﹤0.01% del portafolio de Northern Trust en T3 2026 y fue su posición número 3196.
- Northern Trust reportó por primera vez una posición en Lineage Cell Therapeutics en T2 2013 y desde entonces la ha mantenido en 54 trimestres.
- La posición de Northern Trust en Lineage Cell Therapeutics alcanzó su máximo de USD 4.64 M en T2 2021.
- Al cierre de T3 2026, 143 fondos que sigue Wall St. Rank tenían Lineage Cell Therapeutics en su portafolio.
Según el informe 13F de Northern Trust correspondiente a T3 2026, presentado el 16 nov 2026.